1 / 20

Benefit-Risk Reevaluation of Marketed Drugs

Benefit-Risk Reevaluation of Marketed Drugs. Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June 2000. FDA Presentations: Themes. Benefit-Risk Evaluation of Lotronex Potential Benefits of Lotronex Potential Risks of Lotronex

Olivia
Télécharger la présentation

Benefit-Risk Reevaluation of Marketed Drugs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Benefit-Risk Reevaluation of Marketed Drugs Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June 2000 Victor F. C. Raczkowski, M.D.

  2. FDA Presentations: Themes • Benefit-Risk Evaluation of Lotronex • Potential Benefits of Lotronex • Potential Risks of Lotronex • Benefit-Risk Balance for Lotronex • Risk-Management Options • Assessing the Impact of Risk-Management Interventions Victor F. C. Raczkowski, M.D.

  3. FDA Presentations • Introduction and Benefit-Risk Reevaluation of Marketed Drugs • V Raczkowski, MD, MSc • Lotronex and Serious Adverse Events of the GI Tract • H Gallo-Torres, MD, PhD Victor F. C. Raczkowski, M.D.

  4. FDA Presentations • Risk-Management Options • V Raczkowski, MD, MSc • Medication Guides • N Ostrove, PhD Victor F. C. Raczkowski, M.D.

  5. FDA Presentations • Risk-Intervention Studies • E Rodriguez, MD, MPH • Summary of Issues • V Raczkowski, MD, MSc Victor F. C. Raczkowski, M.D.

  6. Benefits of Lotronex • Lotronex is indicated for the treatment of irritable bowel syndrome (IBS) in women whose predominant bowel symptom is diarrhea • The safety and effectiveness of Lotronex in men have not been established. Victor F. C. Raczkowski, M.D.

  7. Benefits of Lotronex: Issues • Limit administration of Lotronex to target population • Limit administration of Lotronex to responders Victor F. C. Raczkowski, M.D.

  8. Benefits of Lotronex: Issues • If a drug is not effective in a population taking a drug, those patients experience risk without benefit • If a drug is not effective in an individual taking a drug (i.e., the patient is a non-responder), that patient experiences risk without benefit Victor F. C. Raczkowski, M.D.

  9. Limit Lotronex Administrationto Target Population Victor F. C. Raczkowski, M.D.

  10. What is the Target Population? • Target population for Lotronex is women with diarrhea-predominant IBS • Not indicated for women with other subtypes of IBS • Example: Subgroup analyses suggest Lotronex may not be effective in women with IBS who have alternating diarrhea and constipation Victor F. C. Raczkowski, M.D.

  11. Need for Legitimate Diagnosis of Irritable Bowel Syndrome • Lotronex should be used only in women with a genuine diagnosis of diarrhea-predominant irritable bowel syndrome • Not a casual diagnosis of IBS • Not a misdiagnosis of IBS • Identify specific criteria or tests needed for selection of women who might benefit from use? Victor F. C. Raczkowski, M.D.

  12. Other Populations • Not indicated for men: Data suggest Lotronex is not effective in men even at dosages eight times that used in women • Not indicated for pediatric use: Lack of data Victor F. C. Raczkowski, M.D.

  13. Limit Administration ofLotronex to Responders Victor F. C. Raczkowski, M.D.

  14. Lotronex Responders: The Issue • 40% of women with diarrhea-predominant IBS did not improve • 40-50% improved spontaneously or due to other factors (e.g., placebo effect) • Only in 10-20% improvement attributable to Lotronex Victor F. C. Raczkowski, M.D.

  15. Study 3001: Diarrhea-Predominant Subgroup:Monthly Relief of IBS Pain/Discomfort: LOCF Victor F. C. Raczkowski, M.D.

  16. Study 3002: Diarrhea-Predominant Subgroup:Monthly Relief of IBS Pain/Discomfort: LOCF Victor F. C. Raczkowski, M.D.

  17. Responders: Conclusions • Of women with diarrhea-predominant IBS who take Lotronex and improve, 68-80% improve spontaneously or due to other factors not attributable to Lotronex • Many may continue to take Lotronex because of false belief that improvement is due to drug Victor F. C. Raczkowski, M.D.

  18. Responders: Conclusions • These patients are exposed, possibly chronically, to risk without benefit • Terminate treatment in patients who fail to respond to Lotronex? • Identify specific conditions that should be met before drug is used on a long-term basis (e.g., identify responders)? Victor F. C. Raczkowski, M.D.

  19. Benefit: Overall Conclusions • Lotronex is a palliative (not curative) treatment for IBS • Lotronex has not been shown to prevent progression of IBS symptoms • Proportion of women who have benefit attributable to Lotronex is modest Victor F. C. Raczkowski, M.D.

  20. Benefit: Overall Conclusions • Administration of Lotronex only to target population would help optimize benefit-risk ratio • Administration of Lotronex only to true responders would help optimize benefit-risk ratio Victor F. C. Raczkowski, M.D.

More Related